Patents by Inventor Oleg E. Akilov

Oleg E. Akilov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reactive oxygen species production by myeloid-derived suppressor cells as a predictor of patient response to interferon-? therapy
    Patent number: 10627403
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS AS A PREDICTOR OF PATIENT RESPONSE TO INTERFERON-A THERAPY
    Publication number: 20170219585
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Activation of myeloid-derived suppressor cells as a predictor of patient response to interferon-A therapy
    Patent number: 9655950
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: May 23, 2017
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • METHODS FOR DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA
    Publication number: 20160169901
    Abstract: The present invention is based, at least in part, on the discovery of biomarkers identified herein which are associated with cutaneous T-cell lymphoma (CTCL). Accordingly, the present invention provides methods for diagnosing CTCL, e.g., early stage CTCL, including mycosis fungoides (MF) and Sézary syndrome (SS), and to distinguish CTCL from other skin disorders.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 16, 2016
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Larisa J. GESKIN, Oleg E. AKILOV
  • PREDICTORS OF PATIENT RESPONSE TO INTERFERON-A THERAPY
    Publication number: 20150064136
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: The University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Larisa Geskin, Oleg E. Akilov